New and experimental HIV treatments

Other topics in this section

New and experimental HIV treatments: latest news

New and experimental HIV treatments resources

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

  • Researchers stop the only current HIV vaccine efficacy trial

    The US National Institute of Allergy and Infectious Diseases (NIAID) has announced that it is discontinuing the HVTN 505 HIV vaccine trial. This trial, which started in July 2009, has involved 2504 gay and transgender volunteers in 19 US cities. ...

    26 April 2013 | Gus Cairns

  • Gene therapy studies show potential for HIV control without drugs

    Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to HIV infection, the 20th Conference on Retroviruses and Opportunistic Infections ...

    13 March 2013 | Gus Cairns

  • New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

    The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week ...

    10 March 2013 | Liz Highleyman

  • Can people with resistant HIV omit NRTIs when switching from a failing regimen?

    Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and side-effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections ...

    07 March 2013 | Liz Highleyman

  • New pro-drug tenofovir alafenamide appears equally effective but better tolerated

    Tenofovir alafenamide fumarate or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harbouring HIV more easily than the older tenofovir disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with ...

    07 March 2013 | Liz Highleyman

  • New NNRTI MK-1439 shows promise in early clinical trial

    A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated robust antiretroviral activity and good tolerability as monotherapy in a small phase Ib clinical study, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. NNRTIs are generally well ...

    06 March 2013 | Liz Highleyman

  • Dual CCR5/CCR2 inhibitor cenicriviroc has anti-inflammatory as well as anti-HIV effect

    Cenicriviroc, which blocks both CCR5 and CCR2 receptors on immune cells, is effective against HIV, better tolerated than current antiretrovirals and has immunomodulatory activity that may reduce inflammation, according to a presentation yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI ...

    06 March 2013 | Liz Highleyman

  • Australian researchers project that many HIV-positive people will run out of treatment options

    Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in the online edition of AIDS. The research expands upon a study ...

    22 January 2013 | Michael Carter

  • New fixed-dose combination pills measure up to Atripla - corrected version*

    Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week. Amongst them were the 48-week results from the STAR study, an open-label ...

    20 November 2012 | Gus Cairns

  • Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

    The integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and appears to have a high barrier to resistance, according to a presentation ...

    17 September 2012 | Liz Highleyman
More news

New and experimental HIV treatments news selected from other sources

  • Nanoparticles May Transport HIV Meds to the Brain

    Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.

    16 May 2013 | AIDSMeds

  • UPDATE: Sangamo Highlights Encouraging Preliminary Anti-Viral HIV Data

    he data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented at the 16^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).

    15 May 2013 | Benzinga

  • Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist

    Ritonavir, darunavir/ritonavir, and atazanavir/ritonavir all more than tripled exposure of cenicriviroc, an investigational CCR5 and CCR2 receptor antagonist, in 60 healthy volunteers. There were no serious or unexpected adverse events in these 20-day studies.

    14 May 2013 | NATAP

  • Johnson & Johnson allies with biotech startup on HIV drug in China

    The biopharma startup Ascletis has snagged exclusive rights from Johnson & Johnson's ($JNJ) Janssen for an experimental HIV protease inhibitor for the China market. Hangzhou, China-based Ascletis aims to develop the candidate, called TMC310911.

    01 May 2013 | FierceBiotech

  • FDA rejects two of the four drugs in Gilead's blockbuster HIV drug Stribild

    The FDA has handed back a pair of new drug applications from Gilead ($GILD) covering key products used in its blockbuster four-in-one HIV-fighting therapy Stribild.

    30 April 2013 | FierceBiotech

  • Doctors' historic effort to cure child with HIV and leukemia

    A University of Minnesota team performed an unprecedented transplant on Tuesday in an effort to cure a 12-year-old boy who has both HIV and leukemia. Their potential solution: umbilical cord blood containing a protein known to protect a person against HIV.

    25 April 2013 | MPR News

  • New nanotechnique to deliver life-saving drugs to the brain

    In a study published in today's issue of Nature Communications, researchers from FIU's Herbert Wertheim College of Medicine describe a revolutionary technique they have developed that can deliver and fully release the anti-HIV drug AZTTP into the brain.

    22 April 2013 | Phys.org

  • Preparing for Generics: The push for affordable HIV treatment doesn’t end with patent expirations

    The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with the anticipated arrival of generic versions of guidelines- preferred antiretrovirals. However, much preparation is required to maximize price competition, maintain patient choice, and ensure that savings are used to the advantage of people living with HIV.

    11 April 2013 | Treatment Action Group

  • DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs

    The focus of the joint R&D effort is to expedite research into and the development of new maturation inhibitor drugs by combining DFH Pharma's background and experience in HIV therapeutic development with Hetero's world class expertise in product development, medicinal chemistry, manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms.

    04 April 2013 | DFH Pharma press release

  • European CHMP Adopts Positive Opinion for Stribild®, a Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen for the Treatment of HIV-1 Infection

    Gilead Sciences today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorisation Application (MAA) for the once-daily, single tablet regimen Stribild® for the treatment of HIV-1 infection in adult patients who are antiretroviral-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. Stribild combines elvitegravir, an integrase inhibitor, and cobicistat, a pharmacoenhancing agent, with Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)).

    22 March 2013 | Gilead press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.